Pharmaceutical Research

, Volume 27, Issue 12, pp 2657–2669 | Cite as

Poly(ε-caprolactone)-Block-poly(ethyl Ethylene Phosphate) Micelles for Brain-Targeting Drug Delivery: In Vitro and In Vivo Valuation

  • Pengcheng Zhang
  • Luojuan Hu
  • Yucai Wang
  • Jun Wang
  • Linyin Feng
  • Yaping Li
Research Paper



The purpose of this work was to investigate the potential of poly(ε-caprolactone)-block-poly(ethyl ethylene phosphate) (PCL-PEEP) micelles for brain-targeting drug delivery.


The coumarin-6-loaded PCL-PEEP micelles (CMs) were prepared and characterized. The cellular uptake of CMs was evaluated on in vitro model of brain-blood barrier (BBB), and the brain biodistribution of CMs in ICR mice was investigated.


PCL-PEEP could self-assemble into 20 nm micelles in water with the critical micelle concentration (CMC) 0.51 μg/ml and high coumarin-6 encapsulation efficiency (92.5 ± 0.7%), and the micelles were stable in 10% FBS with less than 25% leakage of incorporated coumarin-6 during 24 h incubation at 37°C. The cellular uptake of CMs by BBB model was significantly higher and more efficient than coumarin-6 solution (CS) at 50 ng/ml. Compared with CS, 2.6-fold of coumarin-6 was found in the brains of CM-treated mice, and Cmax of CMs was 4.74% of injected dose/g brain. The qualitative investigation on the brain distribution of CMs indicated that CMs were prone to accumulate in hippocampus and striatum.


These results suggest that PCL-PEEP micelles could be a promising brain-targeting drug delivery system with low toxicity.


biodistribution blood-brain barrier (BBB) micelle polyphosphoester 



The National Basic Research Program of China (2007CB935804 and 2009CB930304), National Natural Science Foundation of China (90713035), and National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”(No 2009ZX09501-024 and 2009ZX09103-066), and Major project of Shanghai Science and Technology Committee (08DZ1980200) are gratefully acknowledged for financial support.


  1. 1.
    Pardridge WM. Brain drug development and brain drug targeting. Pharm Res. 2007;24:1729–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm. 2005;298:274–92.CrossRefPubMedGoogle Scholar
  3. 3.
    Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24:1759–71.CrossRefPubMedGoogle Scholar
  4. 4.
    Hu K, Li JW, Shen YH, Lu W, Gao XL, Zhang QZ, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134:55–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Huwyler J, Wu DF, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA. 1996;93:14164–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999;16:1564–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Ambruosi A, Yamamoto H, Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J Drug Target. 2005;13:535–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Pang ZQ, Lu W, Gao HL, Hu KL, Chen J, Zhang CL, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release. 2008;128:120–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target. 2006;14:97–105.CrossRefPubMedGoogle Scholar
  10. 10.
    Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces. 2008;66:274–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Gao KP, Jiang XG. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006;310:213–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003;55:403–19.CrossRefPubMedGoogle Scholar
  13. 13.
    Liu LH, Guo K, Lu J, Venkatraman SS, Luo D, Ng KC, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2008;29:1509–17.CrossRefPubMedGoogle Scholar
  14. 14.
    Kuroda JI, Kuratsu JI, Yasunaga M, Koga Y, Saito Y, Matsumura Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer. 2009;124:2505–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Fruijtier-Polloth C. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology. 2005;214:1–38.CrossRefPubMedGoogle Scholar
  16. 16.
    Chaubal MV, Sen Gupta A, Lopina ST, Bruley DF. Polyphosphates and other phosphorus-containing polymers for drug delivery applications. Crit Rev Ther Drug Carrier Syst. 2003;20:295–315.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang S, Wan ACA, Xu XY, Gao SJ, Mao HQ, Leong KW, et al. A new nerve guide conduit material composed of a biodegradable poly(phosphoester). Biomaterials. 2001;22:1157–69.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhao Z, Wang J, Mao HQ, Leong KW. Polyphosphoesters in drug and gene delivery. Adv Drug Deliv Rev. 2003;55:483–99.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang YC, Liu XQ, Sun TM, Xiong MH, Wang J. Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J Control Release. 2008;128:32–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang YC, Tang LY, Sun TM, Li CH, Xiong MH, Wang J. Self-assembled micelles of biodegradable triblock copolymers based on poly(ethyl ethylene phosphate) and poly(-caprolactone) as drug carriers. Biomacromolecules. 2008;9:388–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Benny O, Fainaru O, Adini A, Cassiola F, Bazinet L, Adini I, et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol. 2008;26:799–807.CrossRefPubMedGoogle Scholar
  22. 22.
    Song WJ, Du JZ, Liu NJ, Dou S, Cheng J, Wang J. Functionalized diblock copolymer of poly(epsilon-caprolactone) and polyphosphoester bearing hydroxyl pendant groups: synthesis, characterization, and self-assembly. Macromolecules. 2008;41:6935–41.CrossRefGoogle Scholar
  23. 23.
    Demeuse P, Kerkhofs A, Struys-Ponsar C, Knoops B, Remacle C, de Aguilar PV. Compartmentalized coculture of rat brain endothelial cells and astrocytes: a syngenic model to study the blood-brain barrier. J Neurosci Methods. 2002;121:21–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Calabria AR, Weidenfeller C, Jones AR, de Vries HE, Shusta EV. Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. J Neurochem. 2006;97:922–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Patt S, Sampaolo S, TheallierJanko A, Tschairkin I, CervosNavarro J. Angiogenesis triggered by severe chronic hypoxia displays regional differences. J Cereb Blood Flow Metab. 1997;17:801–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Mikhail AS, Allen C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. J Control Release. 2009;138:214–23.CrossRefPubMedGoogle Scholar
  27. 27.
    Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev. 2010;62:503–17.CrossRefPubMedGoogle Scholar
  28. 28.
    Yang XZ, Sun TM, Dou S, Wu J, Wang YC, Wang J. Block copolymer of polyphosphoester and poly(L-lactic acid) modified surface for enhancing osteoblast adhesion, proliferation, and function. Biomacromolecules. 2009;10:2213–20.CrossRefPubMedGoogle Scholar
  29. 29.
    Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol. 2002;64:1355–74.CrossRefPubMedGoogle Scholar
  30. 30.
    Gumbleton M, Audus KL. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci. 2001;90:1681–98.CrossRefPubMedGoogle Scholar
  31. 31.
    Bowman PD, Ennis SR, Rarey KE, Betz AL, Goldstein GW. Brain microvessel endothelial cells in tissue culture: a model for study of blood-brain barrier permeability. Ann Neurol. 1983;14:396–402.CrossRefPubMedGoogle Scholar
  32. 32.
    Perriere N, Demeuse PH, Garcia E, Regina A, Debray M, Andreux JP, et al. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem. 2005;93:279–89.CrossRefPubMedGoogle Scholar
  33. 33.
    Borges N, Shi F, Azevedo I, Audus KL. Changes in brain microvessel endothelial cell monolayer permeability induced by adrenergic drugs. Eur J Pharmacol. 1994;269:243–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Flores-Benitez D, Ruiz-Cabrera A, Flores-Maldonado C, Shoshani L, Cereijido M, Contreras RG. Control of tight junctional sealing: role of epidermal growth factor. Am J Physiol Renal Physiol. 2007;292:F828–36.CrossRefPubMedGoogle Scholar
  35. 35.
    Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol. 2001;280:H434–40.PubMedGoogle Scholar
  36. 36.
    Sobue K, Yamamoto N, Yoneda K, Hodgson ME, Yamashiro K, Tsuruoka N, et al. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res. 1999;35:155–64.CrossRefPubMedGoogle Scholar
  37. 37.
    Lopez-Lopez C, LeRoith D, Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci USA. 2004;101:9833–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Lin JL, Huang YH, Shen YC, Huang HC, Liu PH. Ascorbic acid prevents blood-brain barrier disruption and sensory deficit caused by sustained compression of primary somatosensory cortex. J Cereb Blood Flow Metab. 2010;30:1121–36.CrossRefPubMedGoogle Scholar
  39. 39.
    Raub TJ, Kuentzel SL, Sawada GA. Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astroglioma cells. Exp Cell Res. 1992;199:330–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Honda M, Nakagawa S, Hayashi K, Kitagawa N, Tsutsumi K, Nagata I, et al. Adrenomedullin improves the blood-brain barrier function through the expression of claudin-5. Cell Mol Neurobiol. 2006;26:109–18.CrossRefPubMedGoogle Scholar
  41. 41.
    Abbruscato TJ, Davis TP. Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. J Pharmacol Exp Ther. 1999;289:668–75.PubMedGoogle Scholar
  42. 42.
    Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178–201.CrossRefPubMedGoogle Scholar
  43. 43.
    Ragnarsson EGE, Schoultz I, Gullberg E, Carlsson AH, Tafazoli F, Lerm M, et al. Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis. Lab Invest. 2008;88:1215–26.CrossRefPubMedGoogle Scholar
  44. 44.
    Wang ZJ, Tiruppathi C, Minshall RD, Malik AB. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano. 2009;3:4110–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Lorenz MR, Kohnle MV, Dass M, Walther P, Hocherl A, Ziener U, et al. Synthesis of fluorescent polyisoprene nanoparticles and their uptake into various cells. Macromol Biosci. 2008;8:711–27.CrossRefPubMedGoogle Scholar
  46. 46.
    Pardridge WM. Peptide drug delivery to the brain. New York: Raven; 1991. p. 52–3.Google Scholar
  47. 47.
    De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJAM, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008;29:1912–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997;14:325–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10:317–25.CrossRefPubMedGoogle Scholar
  50. 50.
    Steiniger SCJ, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109:759–67.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Center of Pharmaceutics, Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghaiChina
  2. 2.State Key Laboratory of Drug Research Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghaiChina
  3. 3.University of Sciences and Technology of ChinaHefeiChina

Personalised recommendations